Double antiagrégation plaquettaire pour le traitement et la prévention secondaire de la maladie coronarienne. Indications, modalités et durées de traitement [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
Détails
![Ressource 1](https://serval.unil.ch/static/img/forbidden.png)
Accès restreint UNIL
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_AE3B2E49E3E0
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Double antiagrégation plaquettaire pour le traitement et la prévention secondaire de la maladie coronarienne. Indications, modalités et durées de traitement [Dual antiplatelet therapy for treatment and secondary prevention of coronary artery disease: indications, modalities and duration].
Périodique
Revue Medicale Suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
2016
Volume
12
Numéro
520
Pages
1022-6, 1028-34
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; ReviewPublication Status: ppublish
Résumé
The choice and optimal duration of dualantiplatelet therapy (DAPT) for the treatment of coronary artery disease (CAD) represent a challenging clinical dilemma. Antiplatelet treatment strategies are determined by the clinical setting, patient comorbidities and management strategy. While aspirin remains the cornerstone for secondary prevention of CAD, DAPT significantly reduces recurrent ischemic adverse events at the expense of an increased risk of major bleeding complications. A tailored approach based on individual ischemic and hemorrhagic risk assessment is currently recommended. This review aims to provide a contemporary overview on the current body of evidence concerning DAPT for treatment and secondary prevention of CAD with practical emphasis on current indications, choice, combination and optimal duration of antiplatelet therapy.
Mots-clé
Aspirin/administration & dosage, Aspirin/adverse effects, Coronary Artery Disease/drug therapy, Coronary Artery Disease/prevention & control, Drug Therapy, Combination, Hemorrhage/chemically induced, Humans, Platelet Aggregation Inhibitors/administration & dosage, Platelet Aggregation Inhibitors/adverse effects, Risk Assessment/methods, Secondary Prevention/methods, Time Factors
Pubmed
Site de l'éditeur
Création de la notice
19/10/2016 14:45
Dernière modification de la notice
20/08/2019 16:18